News >

Lisocabtagene Maraleucel Elicits Undetectable MRD in Relapsed/Refractory CLL

Nichole Tucker
Published: Tuesday, Aug 06, 2019

Tanya Siddiqi, MD

Tanya Siddiqi, MD

Lisocabtagene maraleucel (liso-cel; JCAR017) led to undetectable minimal residual disease (MRD) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), according to phase I/II results of the TRANSCEND CLL 004 study (NCT03331198).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication